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Abstract
Synthesis and investigation of antifungal, anticonvulsant and anti-Toxoplasma gondii activities of ten novel (2-
(cyclopropylmethylidene)hydrazinyl)thiazole 3a–3j are presented. Among the derivatives, compounds 3a–3d and 3f–3j
possess very high activity against Candida spp. ATCC with MIC= 0.015–7.81 µg/ml. Compounds 3a–3d and 3f–3j possess
also very high activity towards most of strains of Candida spp. isolated from clinical materials with MIC= 0.015–7.81 µg/
ml. The activity of these compounds is similar and even higher than the activity of nystatin used as positive control.
Additionally, compounds 3c and 3e showed interesting anticonvulsant activities in the MES test, whereas compounds 3f and
3i demonstrated the anticonvulsant activity in PTZ-induced seizures. Noteworthy, none of these compounds impaired
animals’ motor skills in the rotarod test. Moreover, thiazoles 3a, 3h, and 3j showed significant anti-Toxoplasma gondii
activity, with IC50 values 31–52 times lower than those observed for sulfadiazine. The results of the cytotoxicity evaluation,
anti-Candida spp. and anti-Toxoplasma gondii activity studies showed that Candida spp. and Toxoplasma gondii growth
was inhibited at non-cytotoxic concentrations for the mouse L929 fibroblast and the African green monkey kidney (VERO)
cells. Molecular docking studies indicated secreted aspartic proteinase (SAP) as possible antifungal target.
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Introduction
Candida spp. is the most common group of nosocomial
pathogens that cause invasive fungal infection leading to
hospitalizations and death (Richards et al. 2000). The
majority of candidiasis cases are caused by Candida albi-
cans, however non-C. albicans, such as Candida glabrata,
Candida parapsilosis, Candida tropicalis and Candida
krusei has recently been found an important group of
pathogens that also cause bloodstream infections (IC)
(Macphail et al. 2002). The ratio of individual pathogens is
variable and depends on many factors, such as the age of the
patient, geography, underlying diseases and the type of
recently used drugs (Wu et al. 2014). C. glabrata is the
second most commonly isolated pathogen, occurring espe-
cially in the elderly people suffering from cancer and under
azole prophylaxis, while C. parapsilosis occurs mainly in
catheterized neonates in southern Europe, Asia and South
America. In contrast, C. krusei is a particularly common
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pathogen in people undergoing corticosteroid therapy and
with hematologic malignancies (Guinea 2014).
There are many groups of drugs used to fight candide-
mia, however the irresponsible and widespread use of
antifungals has been accompanied by multi-drug resistance
of clinical isolates of Candida spp. (Nucci and Marr 2005).
In 2016, the Infectious Disease Society of America (IDSA)
published new guidelines for the use of echinocandins,
azoles and also lipid formulations of amphotericin B in the
treatment of candidemia, and other forms of invasive can-
didiasis (Pappas et al. 2016).
Epilepsy is a common neurological disorder that affects
millions of people worldwide. This disease is featured by a
strong propensity towards unprovoked seizures which are
caused by various structural or functional impairments
within the brain. Available anti-epileptic drugs are regarded
to be symptomatic treatments being unable to cure epilepsy
or prevent its development and they fail to control epileptic
activity in about 30% of patients. Moreover, many of these
drugs have serious adverse effects that result in poor tol-
erability and a reduced quality of patient’s life, resulting in a
strong medical demand for novel treatment strategies for
epilepsy (Lamberink et al. 2017).
Infections of the central nervous system (CNS) are
regarded as one of major risk factors for seizure onset. So
called “acquired epilepsy” might occur at any age of an
individual’s life and this type of epilepsy might be con-
sidered as an under-recognized long-term complication of
infections within the CNS (Vezzani et al. 2016). It has been
shown that not only bacterial (typical bacterial meningitis,
tuberculosis), viral (HSV, HHV-6), parasitic (cerebral tox-
oplasmosis, neurocysticercosis, and malaria) but also fungal
neuroinfections caused by Candida, Cryptococcus, Cocci-
dioides, Aspergillus, Blastomyces, and Histoplasma may
induce seizures (Sander and Perucca 2003; Bittencourt et al.
1999) that may occur at any stage of fungal infections
(Vezzani et al. 2016).
Taking into consideration a strong link between seizures
and microbial infections, in addition to search for drugs that
have high antifungal activity, we also decided to continue
the search of “hybrid” drug candidates which possess
antifungal, anticonvulsant, and anti-toxoplasmosis proper-
ties. Such compounds seem to be particularly interesting in
terms of their potential development and application in the
treatment of microbial infection-related seizures.
Hydrazinylthiazole moiety seems to be a good scaffold to
generate a variety of antibacterial (Karegoudar et al. 2008;
Mohammad et al. 2015; Zhao et al. 2017; Łączkowski et al.
2016a, 2017), antifungal (Łączkowski et al. 2016b; Carra-
dori et al. 2013; Chimenti et al. 2007), anti-Trypanosoma
cruzi (de Oliveira Filho et al. 2017), and anticancer (Łącz-
kowski et al. 2016c; Łączkowski et al. 2014a) drugs. Our
earlier studies have shown that incorporation of
cyclopentylmethylene and tetrahydro-2H-thiopyran-4-yl
fragments with hydrazinylthiazole moiety was a successful
strategy to receive significant anticonvulsant activity in
mouse models of seizures (Łączkowski et al. 2016d) and
high antifungal activity against clinical isolates of Candida
spp. (Łączkowski et al. 2016a).
Recently, more drugs containing a cyclopropyl group
have reached to the phase of clinical trials. In addition, eight
of the 200 best-selling FDA-approved drugs contain a
cyclopropane ring. A lot of interest in this ring is due to its
unique properties, such as planarity of the cyclopropane
ring, the C–C bonds of character intermediate between σ
and π and sometimes called “banana bonds”, as well as the
C–H bonds shorter and stronger relative to C–H bonds in
alkanes. These unique properties of the cyclopropane sys-
tem make it an interesting substituent in newly designed
drugs, that may result in increased activity, metabolic sta-
bility, bioavailability, brain permeability, and decrease in
lipophilicity, i.e., ability to penetrate through various bio-
logical barriers (Talele 2016).
Considering the above facts we decided to design and
synthesize ten novel hydrazinylthiazole derivatives con-
taining cyclopropyl fragment and investigate their anti-
fungal activity against a panel of reference strains of
nineteen microorganisms from American Type Culture
Collection (ATCC), routinely used for the evaluation of
antimicrobials, and from clinical materials. In the in vivo
part of this study anticonvulsant activity of ten novel thia-
zole derivatives were assessed in mouse models of
chemically-induced and electrically-induced seizures. The
four most active compounds at the highest anticonvulsant
active dose was additionally tested for their influence on
animals’ motor coordination. We also investigated intensity
of Toxoplasma gondii RH virulent strain intracellular pro-
liferation in the VERO host cells.
Experimental
Materials and methods
All experiments were carried out under air atmosphere
unless stated otherwise. Reagents were generally the best
quality commercial-grade products and were used without
further purification. 1H nuclear magnetic resonance (NMR)
(400MHz) and 13C NMR (100MHz) spectra were recorded
on a Bruker Avance III multinuclear instrument. GC-EI-MS
was performed by the Laboratory for Analysis of Organic
Compounds and Polymers of the Centre for Molecular and
Macromolecular Studies of the Polish Academy of Science
in Łódź. MS spectra were recorded on a Finnigan MAT
95 spectrometer. Melting points were determined in open
glass capillaries and are uncorrected. Analytical TLC was
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performed using Macherey-Nagel Polygram Sil G/UV254
0.2 mm plates. Cyclopropanecarboxaldehyde, thiosemi-
carbazide and appropriate bromoketones were commercial
materials (Aldrich).
2-(Cyclopropylmethylidene)hydrazinecarboxamide (2)
Thiosemicarbazide (1.82 g, 20.0 mmol) was added to a
stirred solution of cyclopropanecarboxaldehyde (1) (1.40 g,
20.0 mmol) in absolute ethyl alcohol (30 ml) and then
(1.0 ml) of acetic acid was added. The reaction mixture was
stirred under reflux for 20 h. Next, the reaction mixture was
added to water (50 ml) and neutralized with NaHCO3
solution. The product was extracted with dichloromethane
(2 × 100 ml), the solvent was evaporated in vacuo, and the
solid was washed with diethyl ether to afford the desired
product to yield 2.19 g (77%); mp 124–127 °C; eluent:
dichloromethane/methanol (95:5), Rf= 0.56. 1H NMR
(DMSO-d6, 400MHz); δ (ppm): 0.64–0.70 (m, 2H, CH2);
0.82–0.88 (m, 2H, CH2); 1.51–1.62 (m, 1H, CH); 7.00 (d,
1H, CH, J= 7.5 Hz); 7.44 (bs, 1H, NH2); 7.88 (bs, 1H,
NH2); 10.98 (bs, 1H, NH).
13C NMR (DMSO-d6,
100MHz): δ (ppm) 6.73 (2Ccyclopropyl); 13.79 (Ccyclopropyl);
150.89 (C=N); 177.43 (C=S). Anal. calcd. for C5H9N3S:
C, 41.93; H, 6.33; N, 29.34. Found: C, 41.95; H, 6.30; N,
29.37.
(E)-2-(2-(Cyclopropylmethylene)hydrazinyl)-4-(4-
fluorophenyl)thiazole (3a): typical procedure
Carbothioamide 2 (0.143 g, 1.0 mmol) was added to a stir-
red solution of 2-bromo-1-(4-fluorophenyl)ethanone
(0.217 g, 1.0 mmol) in absolute ethyl alcohol (15 ml). The
reaction mixture was stirred at room temperature for 20 h.
Next, the reaction mixture was added to water (50 ml) and
neutralized with NaHCO3 solution. The product was
extracted with dichloromethane (2 × 100 ml), the solvent
was evaporated in vacuo, and the product was purified on
silica gel column chromatography (230–400 mesh) using
(dichloromethane/methanol, 95:5, Rf= 0.83) to afford the
desired product: 0.18 g, 69%; mp 59–61 °C. 1H NMR
(DMSO-d6, 400MHz); δ (ppm): 0.64–0.70 (m, 2H, CH2);
0.82–0.88 (m, 2H, CH2); 1.51–1.62 (m, 1H, CH); 6.89 (d,
1H, CH, J= 8.32 Hz); 7.19–7.23 (m, 3H, 3CH); 7.83–7.87
(m, 2H, 2CH); 11.52 (bs, 1H, NH). 13C NMR (DMSO-d6,
100MHz): δ (ppm) 6.35 (2Ccyclopropyl); 13.97 (Ccyclopropyl);
102.92 (Cthiazole); 115.84 (d, 2CAr, JC–F= 21 Hz); 127.90 (d,
2CAr, JC–F= 8 Hz); 131.86 (C); 149.46 (Cthiazole); 149.72
(C=N); 160.74 (C–F); 169.00 (C–NH). GC-EI-MS (m/z,
%): 261 [(M+), 35], 194 (80), 152 (100). Anal. calcd. for
C13H12FN3S: C, 59.75; H, 4.63; N, 16.08. Found: C, 59.73;
H, 4.64; N, 16.11.
(E)-4-(4-Bromophenyl)-2-(2-(cyclopropylmethylene)
hydrazinyl)thiazole (3b)
2-Bromo-1-(4-bromophenyl)ethanone was reacted with 2.
Yield: 0.50 g, 78%, (dichloromethane, Rf= 0.49); mp
165–167 °C. 1H NMR (DMSO-d6, 400MHz); δ (ppm):
0.64–0.70 (m, 2H, CH2); 0.82–0.88 (m, 2H, CH2);
1.51–1.62 (m, 1H, CH); 6.92 (d, 1H, CH, J= 7.7 Hz); 7.29
(s, 1H, CH); 7.58 (d, 2H, 2CH, J= 8.6 Hz); 7.76 (d, 2H,
2CH, J= 8.6 Hz); 11.56 (bs, 1H, NH). 13C NMR (DMSO-
d6, 100MHz): δ (ppm) 6.57 (2Ccyclopropyl); 14.05 (Ccyclopro-
pyl); 104.41 (Cthiazole); 121.34 (C); 128.16 (2CAr); 132.03
(2CAr); 133.20 (C); 147.56 (Cthiazole); 151.59 (C=N);
168.99 (C–NH). GC-EI-MS (m/z, %): 321 [(M+), 30], 256
(60), 174 (100). Anal. calcd. for C13H12BrN3S: C, 48.46; H,
3.75; N, 13.04. Found: C, 48.44; H, 3.77; N, 13.08.
(E)-4-(4-Chlorophenyl)-2-(2-(cyclopropylmethylene)
hydrazinyl)thiazole (3c)
2-Bromo-1-(4-chlorophenyl)ethanone was reacted with 2.
Yield: 0.29 g, 52%, (dichloromethane, Rf= 0.48); mp
162–163 °C. 1H NMR (DMSO-d6, 400MHz); δ (ppm):
0.64–0.70 (m, 2H, CH2); 0.82–0.88 (m, 2H, CH2);
1.51–1.62 (m, 1H, CH); 6.89–6.99 (m, 1H, CH); 7.29 (s,
1H, CH); 7.45 (d, 2H, 2CH, J= 8.36 Hz); 7.82 (d, 2H,
2CH, J= 8.36 Hz); 11.63 (bs, 1H, NH). 13C NMR (DMSO-
d6, 100MHz): δ (ppm) 6.49 (2Ccyclopropyl); 14.02 (Ccyclopro-
pyl); 104.22 (Cthiazole); 127.78 (2CAr); 129.08 (2CAr); 132.52
(C); 133.32 (C); 148.30 (Cthiazole); 150.83 (C=N); 169.02
(C–NH). GC-EI-MS (m/z, %): 277 [(M+), 45], 210 (100),
174 (55), 168 (65). Anal. calcd. for C13H12ClN3S: C, 56.21;
H, 4.35; N, 15.13. Found: C, 56.20; H, 4.39; N, 15.16.
(E)-2-(2-(Cyclopropylmethylene)hydrazinyl)-4-p-
tolylthiazole (3d)
2-Bromo-1-(4-methylphenyl)ethanone was reacted with 2.
Yield: 0.36 g, 70%, (dichloromethane, Rf= 0.24); mp
158–160 °C. 1H NMR (DMSO-d6, 400MHz); δ (ppm):
0.64–0.70 (m, 2H, CH2); 0.82–0.88 (m, 2H, CH2);
1.51–1.62 (m, 1H, CH); 2.31 (s, 3H, CH3); 6.94 (d, 1H, CH,
J= 7.76 Hz); 7.14 (s, 1H, CH); 7.20 (d, 2H, 2CH, J=
8.00 Hz); 7.69 (d, 2H, 2CH, J= 8.00 Hz); 11.47 (bs, 1H,
NH). 13C NMR (DMSO-d6, 100MHz): δ (ppm) 6.74
(2Ccyclopropyl); 14.12 (Ccyclopropyl); 21.28 (C); 103.01 (Cthia-
zole); 126.24 (2CAr); 129.74 (2CAr); 130.03 (C); 138.26 (C);
146.71 (Cthiazole); 153.45 (C=N); 168.87 (C–NH). GC-EI-
MS (m/z, %): 257 [(M+), 55], 190 (100), 148 (90). Anal.
calcd. for C14H15N3S: C, 65.34; H, 5.87; N, 16.33. Found:
C, 65.36; H, 5.85; N, 16.35.
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(E)-2-(2-(Cyclopropylmethylene)hydrazinyl)-4-(4-
(trifluoromethyl)phenyl)thiazole (3e)
2-Bromo-1-(4-trifluoromethylphenyl)ethanone was reacted
with 2. Yield: 0.57 g, 92%, (dichloromethane, Rf= 0.46);
mp 132–134 °C. 1H NMR (DMSO-d6, 400MHz); δ (ppm):
0.64–0.70 (m, 2H, CH2); 0.82–0.88 (m, 2H, CH2);
1.51–1.62 (m, 1H, CH); 6.91 (d, 1H, CH, J= 8.0 Hz); 7.46
(s, 1H, CH); 7.74 (d, 2H, 2CH, J= 8.6 Hz); 8.03 (d, 2H,
2CH, J= 8.6 Hz); 11.62 (bs, 1H, NH). 13C NMR (DMSO-
d6, 100MHz): δ (ppm) 6.38 (2Ccyclopropyl); 13.98 (Ccyclopro-
pyl); 105.97 (Cthiazole); 123.46 (C); 125.99 (2CAr); 126.45
(2CAr); 127.91 (q, C–F, JC–F= 32 Hz); 138.91 (C); 149.27
(Cthiazole); 149.72 (C=N); 169.18 (C–NH). GC-EI-MS (m/z,
%): 311 [(M+), 35], 244 (100), 202 (60). Anal. calcd. for
C14H12F3N3S: C, 54.01; H, 3.89; N, 13.50. Found: C, 53.98;
H, 3.87; N, 13.54.
(E)-2-(2-(Cyclopropylmethylene)hydrazinyl)-4-(4-
methoxyphenyl)thiazole (3f)
2-Bromo-1-(4-methoxyphenyl)ethanone was reacted with 2.
Yield: 0.38 g, 70%, (dichloromethane, Rf= 0.21); mp
149–152 °C. 1H NMR (DMSO-d6, 400MHz); δ (ppm):
0.64–0.70 (m, 2H, CH2); 0.82–0.88 (m, 2H, CH2);
1.51–1.62 (m, 1H, CH); 6.96 (d, 3H, 3CH, J= 8.9 Hz);
7.06 (s, 1H, CH); 7.73 (d, 2H, 2CH, J= 8.9 Hz); 11.56 (bs,
1H, NH). 13C NMR (DMSO-d6, 100MHz): δ (ppm) 6.74
(2Ccyclopropyl); 14.14 (Ccyclopropyl); 55.70 (C); 101.84 (Cthia-
zole); 114.56 (2CAr); 125.42 (C); 127.78 (2CAr); 146.43
(Cthiazole); 153.46 (C=N); 159.80 (C–O); 168.81 (C–NH).
GC-EI-MS (m/z, %): 273 [(M+), 80], 206 (85), 164 (100),
149 (45). Anal. calcd. for C14H15N3OS: C, 61.51; H, 5.53;
N, 15.37. Found: C, 61.53; H, 5.50; N, 15.40.
(E)-2-(2-(Cyclopropylmethylene)hydrazinyl)-4-(2,4-
difluorophenyl)thiazole (3g)
2-Bromo-1-(2′4′-difluorophenyl)ethanone was reacted with
2. Yield: 0.31 g, 55%, (dichloromethane, Rf= 0.46); mp
97–100 °C. 1H NMR (DMSO-d6, 400MHz); δ (ppm):
0.64–0.70 (m, 2H, CH2); 0.82–0.88 (m, 2H, CH2);
1.51–1.62 (m, 1H, CH); 6.92 (d, 1H, CH, J= 7.7 Hz);
7.08–7.18 (m, 2H, 2CH); 7.26–7.36 (m, 1H, CH); 7.95–8.02
(m, 1H, CH); 11.59 (bs, 1H, NH). 13C NMR (DMSO-d6,
100MHz): δ (ppm) 6.38 (2Ccyclopropyl); 13.97 (Ccyclopropyl);
104.88 (t, C, J= 27.0 Hz); 107.30 (d, C, J= 30.0 Hz);
112.20 (d, C, JC–F= 21.0 Hz); 119.61 (C); 130.82 (C);
143.60 (C); 149.67 (C); 159.52 (dd, C, J1= 13.0 Hz, J2=
167.0 Hz); 162.00 (dd, C, J1= 14.0 Hz, J2= 162.0 Hz);
168.31 (C–NH). GC-EI-MS (m/z, %): 279 [(M+), 35], 212
(85), 170 (100). Anal. calcd. for C13H11F2N3S: C, 55.90; H,
3.97; N, 15.04. Found: C, 55.88; H, 3.98; N, 15.07.
(E)-4-(2-(2-(Cyclopropylmethylene)hydrazinyl)thiazol-4-yl)
benzonitrile (3h)
4-(Bromoacetyl)benzonitrile was reacted with 2. Yield:
0.54 g, 99%, (dichloromethane, Rf= 0.24); mp 168–171 °C.
1H NMR (DMSO-d6, 400MHz); δ (ppm): 0.64–0.70 (m,
2H, CH2); 0.82–0.88 (m, 2H, CH2); 1.51–1.62 (m, 1H, CH);
6.96 (d, 1H, CH, J= 7.8 Hz); 7.53 (s, 1H, CH); 7.84 (d, 2H,
2CH, J= 8.7 Hz); 7.98 (d, 1H, CH, J= 8.7 Hz); 11.49 (bs,
1H, NH). 13C NMR (DMSO-d6, 100MHz): δ (ppm) 6.49
(2Ccyclopropyl); 14.02 (Ccyclopropyl); 107.21 (Cthiazole); 110.02
(C); 119.45 (C); 126.66 (2CAr); 133.11 (2CAr); 138.82 (C);
148.28 (Cthiazole); 150.67 (C=N); 169.18 (C–NH). GC-EI-
MS (m/z, %): 268 [(M+), 35], 201 (100), 159 (80). Anal.
calcd. for C14H12N4S: C, 62.66; H, 4.51; N, 20.88. Found:
C, 62.66; H, 4.50; N, 20.92.
(E)-4-(4-Azidophenyl)-2-(2-(cyclopropylmethylene)
hydrazinyl)thiazole (3i)
2-Bromo-1-(4-azidophenyl)ethanone was reacted with 2.
Yield: 0.14 g, 83%, (dichloromethane, Rf= 0.31); mp
124–126 °C. 1H NMR (DMSO-d6, 400MHz); δ (ppm):
0.64–0.70 (m, 2H, CH2); 0.82–0.88 (m, 2H, CH2);
1.51–1.62 (m, 1H, CH); 6.89 (d, 1H, CH, J= 7.44 Hz);
7.13 (d, 2H, 2CH, J= 8.92 Hz); 7.20 (s, 1H, CH); 7.85 (d,
2H, 2CH, J= 8.92 Hz); 11.54 (bs, 1H, NH). 13C NMR
(DMSO-d6, 100MHz): δ (ppm) 6.36 (2Ccyclopropyl); 13.98
(Ccyclopropyl); 103.07 (Cthiazole); 119.74 (2CAr); 127.55
(2CAr); 132.36 (C); 138.64 (C); 149.45 (Cthiazole); 149.96
(C=N); 168.95 (C–NH). GC-EI-MS (m/z, %): 284 [(M+),
30], 256 (100), 188 (65). Anal. calcd. for C13H12N6S: C,
54.91; H, 4.25; N, 29.56. Found: C, 54.94; H, 4.27; N,
29.61.
(E)-2-(2-(Cyclopropylmethylene)hydrazinyl)-4-(4-
nitrophenyl)thiazole (3j)
2-Bromo-1-(4-nitrophenyl)ethanone was reacted with 2.
Yield: 0.56 g, 98%, (dichloromethan, Rf= 0.24); mp
168–171 °C. 1H NMR (DMSO-d6, 400MHz); δ (ppm):
0.64–0.70 (m, 2H, CH2); 0.82–0.88 (m, 2H, CH2);
1.51–1.62 (m, 1H, CH); 6.93 (d, 1H, CH, J= 7.72 Hz);
7.61 (s, 1H, CH); 8.07 (d, 2H, 2CH, J= 9.0 Hz); 8.25 (d,
2H, 2CH, J= 9.0 Hz); 11.64 (bs, 1H, NH). 13C NMR
(DMSO-d6, 100MHz): δ (ppm) 6.49 (2Ccyclopropyl); 14.02
(Ccyclopropyl); 108.19 (Cthiazole); 124.47 (2CAr); 126.81
(2CAr); 140.85 (C); 146.61 (C); 148.21 (Cthiazole); 150.55
(C=N); 169.25 (C–NH). GC-EI-MS (m/z, %): 288 [(M+),
45], 221 (100), 174 (40). Anal. calcd. for C13H12N4O2S: C,
54.15; H, 4.20; N, 19.43. Found: C, 54.15; H, 4.21; N,
19.45.
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Microbiology
The examined compounds 3a–3j were screened in vitro for
antibacterial and antifungal activities using the broth
microdilution method according to European Committee on
Antimicrobial Susceptibility Testing (EUCAST) (EUCAST
2003) and Clinical and Laboratory Standards Institute
guidelines (CLSI 2012) against reference strains of micro-
organisms from American Type Culture Collection
(ATCC), including fungi belonging to yeasts (Candida
albicans ATCC 2091, Candida albicans ATCC 10231,
Candida parapsilosis ATCC 22019 and Candida krusei
ATCC 14243).
In the study of antifungal activity of the compounds 3a–
3j, 15 clinical strains of different species of yeasts from
Candida species, namely C. albicans, C. dubliniensis C.
famata, C. inconspicua, C. krusei, C. tropicalis, C. glab-
rata, C. lambica, C. kefyr, C. lusitaniae, C. parapsilosis, C.
guilliermondii, C. lusitaniae, C. pulcherrima and C. sake
were also used. These fungi were isolated by the author
(from Department of Pharmaceutical Microbiology of
Medical University in Lublin, Poland) from different clin-
ical materials, e.g., from upper respiratory tract of hospita-
lized patients including cancer patients (i.e., with non-small
cell lung cancer or hematological malignancies). Some
patients were after pre-operative or post-operative che-
motherapy (treated with etoposide or cis-platin given in
doses according to the standard procedures), patients with
chronic hepatitis C (undergoing peginterferon and ribavirin
therapy or without antiviral therapy), patients with diabetes,
elderly people, aged of 65 years old or older, staying in
close population, such as a care centre and people staying
outside the home care. The Ethical Committee of the
Medical University of Lublin approved the study protocol
(No. KE-0254/75/2011). The isolates were identified by
standard diagnostic methods—biochemical microtest, e.g.,
API 20C AUX, ID 32C, API Candida (bioMérieux) on the
basis of assimilation of various substrates. All the used
microbial cultures were first subcultured on nutrient agar or
Sabouraud agar for bacteria and fungi, respectively. The
RPMI 1640 with MOPS (for fungi) were inoculated with
the suspensions of fungal species. Microbial suspensions
were prepared in sterile saline (0.85% NaCl) with an optical
density of 0.5 McFarland standard scale (Wiegand et al.
2008). Samples containing examined compounds were
dissolved in dimethyl sulfoxide (DMSO). Furthermore,
fungal suspensions were put onto Petri dishes with solid
media containing 2 mg/ml of the tested compounds fol-
lowed incubation under appropriate conditions. The inhi-
bition of microbial growth was judged by comparison with
a control culture prepared without any sample tested. Nys-
tatin (Sigma) was used as a reference antifungal compound.
Subsequently MIC minimal inhibitory concentration (MIC)
of the compounds was examined by the microdilution broth
method, using their two-fold dilutions in RPMI 1640 broth
with MOPS prepared in 96-well polystyrene plates. Final
concentrations of the compounds ranged from 1000 to
0.0038 µg/ml. Microbial suspensions were prepared in
sterile saline with an optical density of 0.5 McFarland
standard. Next fungal suspension was added per each well
containing broth and various concentrations of the exam-
ined compounds. After incubation, the MIC was assessed
spectrophotometric as the lowest concentration of the
samples showing complete fungal growth inhibition.
Appropriate DMSO, growth and sterile controls were car-
ried out. The medium with no tested substances was used as
a control (Wiegand et al. 2008). The minimal fungicidal
concentration (MFC) are defined as the lowest concentra-
tion of the compounds that is required to kill a particular
fungal species. MFC was determined by removing the
culture using for MIC determinations from each well and
spotting onto appropriate agar medium. The plates were
incubated. The lowest compounds concentration with no
visible growth observed was assessed as a fungicidal con-
centration. All the experiments were repeated three times
and representative data are presented.
In this study, no bioactivity was defined as a MIC >
1000 µg/ml, mild bioactivity as a MIC in the range
501–1000 µg/ml, moderate bioactivity with MIC from 126
to 500 µg/ml, good bioactivity as a MIC in the range
26–125 µg/ml, strong bioactivity with MIC between 10 and
25 µg/ml and very strong bioactivity as a MIC < 10 µg/ml.
The MFC/MIC ratios were calculated in order to determine
fungicidal (MFC/MIC ≤ 4) or fungistatic (MFC/MIC > 4)
effect of the tested compounds (O’Donnell et al. 2010).
In vivo pharmacology
Animals
For in vivo tests that assessed anticonvulsant properties of
the test compounds 3a–3j adult male Albino Swiss (CD-1)
mice weighing between 18 and 22 g were used. The animals
were housed in groups of ten mice per cage at room tem-
perature of 22 ± 2 °C, under light/dark (12:12) cycle. The
animals had free access to food and tap water before the
experiments. The ambient temperature of the experimental
room and humidity (50 ± 10%) were kept consistent
throughout all the tests. For behavioral experiments the
animals were selected randomly. Each experimental group
consisted of 4–8 animals/dose. The experiments were per-
formed between 9 AM and 2 PM. Immediately after the
in vivo assay the animals were euthanized by cervical dis-
location. All procedures were approved by the Local Ethics
Committee of the Jagiellonian University in Krakow (34/
2018, 1.02.2018)) and the treatment of animals was in full
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accordance with ethical standards laid down in respective
Polish and EU regulations (Directive No. 86/609/EEC).
Chemicals used in pharmacological tests
For in vivo tests the compounds 3a–3j were prepared in 1%
Tween 80 solution (POCH, Poland) and they were admi-
nistered by the intraperitoneal route. Control mice received
1% Tween 80. Pentylenetetrazole (PTZ), pilocarpine
hydrochloride and scopolamine butylbromide were pro-
vided by Sigma Aldrich (Poland). For the tests they were
prepared in 0.9% saline (Polfa Kutno, Poland). PTZ and
pilocarpine were administered 60 min after the test com-
pound or vehicle. To assess anticonvulsant properties of the
test compounds anticonvulsant screening was conducted.
Four assays were used: PTZ, maximal electroshock seizure
(MES), 6-Hz and pilocarpine tests. In these assays the dose
of 100 mg/kg was chosen as a starting dose. If it turned out
to be effective, a lower dose (30 mg/kg) was also tested.
PTZ seizure test
The test was performed according to a method previously
described (Sałat et al. 2005). Clonic convulsions were
induced by the subcutaneous (sc) administration of PTZ at a
dose of 100 mg/kg. After PTZ injection, each mouse was
immediately placed in a transparent Plexiglas cage (30 ×
20 × 15 cm) and was observed during the next 30 min for
the occurrence of clonic seizures. Clonic seizures were
defined as clonus of the whole body lasting more than 3 s,
with an accompanying loss of righting reflex. Latency time
to first clonus and the number of seizure episodes were
noted and compared between vehicle-treated and drug-
treated groups.
Maximal electroshock seizure test
MES test was performed according to a method previously
described (Sałat et al. 2005). In this test vehicle-treated mice
and drug-treated mice received a stimulus of 25 mA deliv-
ered by an electroshock generator (Hugo Sachs rodent
shocker, Germany) to induce maximal seizures (tonic
extension) of hind limbs. Electroconvulsions were produced
with the use of auricular electrodes and the stimulus dura-
tion was 0.2 s. Tonic extension of the hind limbs was
regarded as the endpoint for this procedure.
6-Hz test
This test was performed according to (Barton et al. 2001). It
is an alternative electroshock paradigm that involves low-
frequency (6 Hz), long-duration (3 s) electrical stimulation.
Corneal stimulation (0.2 ms-duration monopolar rectangular
pulses at 6 Hz for 3 s) was delivered by a constant-current
device. During electrical stimulation mice were manually
restrained and released into the observation cage immedi-
ately after current application. At the time of drug admin-
istration a drop of 0.5% tetracaine (Altacaine sterile
solution, Altaire Pharmaceuticals Inc., USA) was applied
into the eyes of all animals. Prior to the placement of cor-
neal electrodes, a drop of 0.9% saline was applied on the
eyes. In this model seizures manifest in ‘stunned’ posture
associated with rearing, forelimb automatic movements and
clonus, twitching of the vibrissae and Straub-tail. At the end
of the seizure episode the animals resume their normal
exploratory behavior. In this test protection against a seizure
episode is considered as the end point and animals are
considered to be protected if they resume their normal
exploratory behavior within 10 s after electrical stimulation.
Pilocarpine-induced seizures
In this test the mice were pretreated with the investigated
compound or vehicle and 60 min later they received pilo-
carpine (400 mg/kg, ip). To avoid cholinergic side-effects:
peripheral toxicity and diarrhea, masticatory and stereo-
typed movements, animals treated with pilocarpine also
received scopolamine butylbromide (1 mg/kg, ip) which
was injected 45 min before pilocarpine. After the adminis-
tration of the convulsant, the mice were observed during the
next 60 min for behavioral changes. Latency time to the
onset of status epilepticus was considered as the endpoint in
this test (Wilhelm et al. 2010).
Rotarod test
The test was performed according to the method recently
described (Sałat et al. 2005). The mice were trained daily
for 3 consecutive days on the rotarod apparatus (Rotarod
apparatus, May Commat RR0711, Turkey; rod diameter:
2 cm) rotating at a constant speed of 18 rotations per minute
(rpm). During each training session, the animals were
placed on a rotating rod for 3 min with an unlimited number
of trials. The proper experimentation was conducted 24 h
after the final training trial. Briefly, 60 min before the
rotarod test the mice were pretreated with the test compound
(100 mg/kg) and then, they were tested on the rotarod
apparatus revolving at 6, 18, and 24 rpm. Motor impair-
ments, defined as the inability to remain on the rotating rod
for 1 min were measured and mean time spent on the rod
was counted in each experimental group.
Data analysis
Data analysis of the results obtained in behavioral tests was
provided by GraphPad Prism Software (ver. 5, CA, USA).
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The results were statistically evaluated using one-way
analysis of variance (ANOVA), followed by Dunnett’s
post-hoc comparison. P < 0.05 was considered significant.
Antiparasitic activity
Cell and parasite culture
L929 cell line (ATCC® CCL-1™) was cultured in IMDM
(IMDM/10%FBS/P/S) (Iscove’s Modified Dulbecco’s
Medium—Biowest) culture medium with the addition of
10% FBS (Fetal Bovine Serum—Biowest), 100 μg/ml
streptomycin (Sigma), 100 U/ml penicillin (Sigma). Vero
cell line (ATCC® CCL-81™) were maintained in EMEM
(EMEM/10%FBS/P/S) (Eagle’s Minimum Essential Med-
ium ATCC® 30-2003™) culture medium supplemented
with 10% FBS, 100 μg/ml streptomycin, 100 U/ml peni-
cillin. Both cells line were trypsinized twice a week, then
seeded in T25 cell culture flask [Falcon], density 1 × 106/
flask and incubated for 24–48 h at 37 °C and 5 or 10% CO2
to achieve a confluent monolayer. Female BALB/cW mice,
aged 8–12 weeks were bred as homozygotes, under con-
ventional conditions in the animal facility of the Faculty of
Biology and Environmental Protection, University of Lodz.
Animal experiments were conducted according to guide-
lines provided by the Polish Local Ethics Commission for
Experiments on Animals No. 9 in Lodz (agreement 67/
ŁB80/2017). Tachyzoites of Toxoplasma gondii (Tg) viru-
lent RH strain (ATCC® 50174™) were propagate by inte-
peritional inoculation of mice, dose per mouse 5 × 106 Tg
tachyzoite in 200 μl of PBS (PBS/5%FBS/P/S) (Dulbecco’s
Phosphate Buffered Saline, w/o magnesium and calcium—
Biowest) supplemented with 5% FBS, 100 μg/ml strepto-
mycin, 100 U/ml penicillin. The mice were sacrificed after
3–4 days by the cervical dislocation, and then parasites were
harvested from peritoneal cavity by lavage with 10 ml of
PBS/5%FBS/P/S and counted using haemocytometer. For
further testing density of Tg tachyzoites was adjusted to 1 ×
106/ml in IMDM (IMDM/5%FBS/P/S) medium supple-
mented with 5% FBS, 100 μg/ml streptomycin, 100 U/ml
penicillin (Dzitko et al. 2014).
Compounds and drug preparation for MTT and [3H]-uracil
incorporation assay
Compounds (3a–3j) were dissolved in dimethyl sulfoxide
(DMSO) (Sigma) 5 mg/ml. Final concentration of DMSO
was not higher than 0.625% in IMDM/5%FBS/P/S or RPMI
1640 without phenol red (Biowest) (RPMI(w/oPhR)/ 10%
FBS/P/S) culture medium supplemented with 10% FBS,
100 μg/ml streptomycin, 100 U/ml penicillin. Sulfadiazine
(S8626, Sigma) was dissolved in 1M sodium hydroxide
(NaOH) (Sigma) 100 mg/ml. Final concertation of NaOH
was not higher than 2.5% in IMDM/5%FBS/P/S.
[3H]-Uracil incorporation assay
Vero cells were seeded in a 96-well tissue culture plate
(Falcon) 100 μl/well from density 1 × 105/ml and incubated
for 24 h at 37 °C and 5% CO2 to achieve a confluent
monolayer. Afterwards, the culture medium was replaced
with 100 μl per well 1 × 106/ml Tg in IMDM/5%FBS/P/S
and incubated for 1 h at 37 °C and 10% CO2. After incu-
bation 100 μl/well solutions of the compounds and drug
were added. The dilutions of tested compounds (final con-
centrations range 0.00–31.25 μg/ml) and sulfadiazine (final
concentrations range 0.00–2500.00 μg/ml) were prepared in
IMDM/5%FBS/P/S. Then, plates were incubated for a fur-
ther 48 h under the previously mentioned conditions. After
that, 25 μl/well of [5,6-3H]-uracil (42.3 Ci/mmol) (Perki-
nElmer) was added, and incubated for 20 h at 37 °C and
10% CO2. Plates were frizzed at −20 °C for a next 24 h, and
then thawed in room temperature, cells and supernatants
were harvested on glass fiber filters (Wallac Oy) and
counted in scintillation counter (Wallac Oy, Turku, Fin-
land). The results were presented as a percentage (%) of
proliferated parasite and the half maximal inhibitory con-
centration (IC50) anti-Tg were established. Each experiment
was performed in triplicate. Statistical analyses and graphs
were performed using GraphPad Prism version 7.00 for
Windows (GraphPad Software, San Diego, CA, USA)
(Dzitko et al. 2014).
Cytotoxicity evaluation
Cytotoxicity was evaluated using the MTT assay, which is
based on the ability of live cells to convert the water-soluble
tetrazolium salt (MTT) ((3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide)—Sigma) to the water-
insoluble formazan crystals by the mitochondrial dehy-
drogenase enzyme. The colour intensity of the solution after
dissolution of the crystals is measured spectro-
photometrically and corresponds to cell viability. The MTT
assay is the most popular test used for the evaluation of
cytotoxic activity according to the ISO standard 10993-
5:2009(E). The assay was performed using two cell lines,
L929 (ATCC® CCL-1™) and Vero (ATCC® CCL-81™).
Cells were lead to a density of 1 × 105/ml, L929 in IMDM/
10%FBS/P/S but Vero in EMEM/10%FBS/P/S, and their
suspension was seeded in a 96-well tissue culture plate
(Falcon) 100 μl/well and incubated for 24 h at 37 °C and 5
or 10% CO2 to achieve a confluent monolayer. Afterwards,
the culture medium was replaced with solutions of the
compounds in RPMI(w/oPhR)/10%FBS/P/S medium at
concentrations of 0–31.25 μg/ml and the cells were
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incubated for a further 24 h at 37 °C and 5% CO2. Further
5 mg/ml MTT solution was prepared and added to the
culture in a volume of 10 μl/well. The plates prepared in this
way were incubated under the previously mentioned con-
ditions for 4 h. After incubation, the plates were centrifuged
for 15 min at 2500 rpm, then the supernatants were
removed. The resulting formazan crystals were dissolved by
adding 150 μl DMSO to each well, the plates were gently
mixed, then 25 μl 0.1 M glycine buffer (pH= 10.5) (Sigma)
was added. Optical density was measured using the ELISA
plate reader (Multiskan EX, Labsystems, Vienna, VA,
USA) at 570 nm. The results were presented as a percentage
(%) of viable cells. Each experiment was performed in
triplicate.
Automated docking setup
Flexible docking was performed by means of the FlexX
(Kramer et al. 1999) program as implemented in LeadIT
software package (LeadIT 2012). Models of the secreted
aspartic proteinase (SAP), and N-myristoyltransferase
(NMT), and calcium channel receptor binding sites based
on the structure deposited in the Protein Data Bank under
the 1EAG, 1IYL, and 5IWP were employed. The active
sites were defined to include all atoms within 6.5 Å radius
of the native ligands. The first 100 top ranked docking poses
were saved for each docking run. For all compounds their
protonated forms were considered, as recommended by
FlexX program.
Results and discussion
Chemistry
2-(Cyclopropylmethylidene)hydrazinecarboxamide (2) was
readily synthesized in high yield by heating of ethanolic
solution of cyclopropanecarboxaldehyde (1) and thiosemi-
carbazide containing catalytic amount of glacial acetic acid.
In the next step Hantzsch cyclization reaction of hydrazi-
necarbothioamide 2 with appropriate para-substituted bro-
moacetophenones in ethanolic solution and under room
temperature produced (2-(cyclopropylmethylidene)-hydra-
zinyl)thiazoles 3a–3j with high yield (52–99%) and with
high chemical purity. The reaction pathway has been
summarized in Scheme 1. All obtained products were pur-
ified on silica gel column chromatography, and fully char-
acterized spectroscopically using 1H and 13C NMR, GC-EI-
MS, and elemental analyses.
In the 1H NMR spectrum of compound 2, three char-
acteristic signals derived from the NH2 and NH groups at
7.44, 7.88, and 10.98 ppm can be observed. These three
signals are the result of the exchange of a hydrogen atom
between the NH2 group and the sulfur atom, and is a
characteristic feature for hydrazinecarbothioamides. Also
1H NMR spectra of (2-(cyclopropylmethylidene)hydrazi-
nyl)thiazole (3a–3j) showed characteristic singlet at δ
(7.06–7.61) ppm due to the presence of the H-5 atom in the
thiazole ring and broadened hydrazine NH singlet at δ
(11.47–11.64) ppm. The 13C NMR of carbon atoms present
in C=N group resonates around 150 ppm which proves that
the conversion of substrates to the expected products was
successful. The [M+] peaks were observed in the mass
spectra of all compounds, confirming the assigned struc-
tures. Purity of the products was confirmed by the elemental
analyses, whose results were in good agreement with the
calculated values. All reactions were repeated at least two
times and are fully reproducible.
Biological evaluation
Antifungal activity
On the basis of MIC obtained by the broth microdilution
method, it was shown that compounds 3a–d and 3f–j pos-
sess strong or very strong activity against Candida spp.
ATCC with MIC= 0.015–7.81 µg/ml (Table 1) and MFC
= 0.03–31.25 µg/ml (Table 2). In addition, most substances
exhibited fungicidal activity (MFC/MIC= 1–4), and some
of them showed fungistatic effect (MFC/MIC= 8–16)
(Table 2). The activity of these compounds is similar and
even higher than the activity of nystatin used as positive
control.
The tested compounds 3a–d and 3f–j possess very strong
activity towards most of strains of Candida spp. isolated
from clinical materials. (namely C. albicans, C. dubliniensis
C. famata, C. inconspicua, C. krusei, C. tropicalis, C.
lusitaniae, C. parapsilosis, C. guilliermondii, C. lusitaniae,
and C. sake) with the same value of MIC= 0.015–7.81 µg/
ml and MFC= 0.015–125 µg/ml (Table 2). The antifungal
Scheme 1 Synthesis of the
target compounds 3a–3j
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effect was both fungicidal (MFC/MIC= 1–4) and fungi-
static (MFC/MIC= 8–128) (Table 3). The activity of these
substances was also similar to nystatin. However, these
compounds indicated weaker or none activity against other
clinical isolates of Candida, such as C. kefyr, C. pulcher-
rima, C. glabrata, and C. lambica. The strong to medium
activity showed only compounds 3d, 3f, 3h, and 3i towards
C. kefyr and 3j towards C. pulcherrima with MIC=
1.95–125 µg/ml.
In addition, compound 3e was found to be inactive
against all tested strains of Candida, as well as, all com-
pounds were inactive towards C. glabrata ATTC 90030,
which is naturally insensitive to azole-derived antifungal
agents (Tumbarello et al. 2008).
The structure-activity relationship (SAR) analysis
showed that in the case of 3a–3d and 3f–3j derivatives, the
type of substituent does not affect the activity. However, it
can be seen that compound 3e containing the tri-
fluoromethyl substituent did not show any activity, and the
only explanation of this fact is that this group is sterically
hindered.
Anticonvulsant activity
In the PTZ model of chemically-induced seizures an overall
effect of treatment on latency time to first clonus (F[12,58]
= 4.967, p < 0.0001) and number of seizure episodes (F
[12,56]= 3.137, p < 0.01) was observed. Two compounds:
3f and 3i showed anticonvulsant properties and 3i was more
efficacious in this respect. These two agents significantly
prolonged latency time to first clonus (Fig. 1a) and reduced
the number of seizure episodes (Fig. 1b). Other compounds
tested were not effective in this assay.
The compounds 3c and 3e demonstrated the highest
anticonvulsant activity in MES test. At the dose 100 mg/kg
they reduced seizures in 75% and 63% of animals,
respectively, but the dose 30 mg/kg of each compound was
not active (Table 3). Other compounds tested at 100 mg/kg
showed lower efficacy in the MES test.
In the 6-Hz test the anticonvulsant activity of the test
compounds was marginal (Table 4). Only the compound 3i
at the dose of 100 mg/kg protected 75% of animals from
seizures in this test.
Four compounds which showed the highest antic-
onvulsant activity in PTZ, MES or 6-Hz tests: 3c, 3e, 3f,
and 3i were also assessed for their potential anticonvulsant
activity in pilocarpine-induced seizure model. One-way
ANOVA revealed an overall effect of treatment (F[4,37]=
2.747, p < 0.05) but the post-hoc analysis did not show
statistically significant anticonvulsant effects of the com-
pounds tested (Fig. 2a).
Table 1 The activity data
expressed as MIC (µg/ml)
against the reference and clinical
strains of fungi
Species MIC (µg/ml) of the tested compounds
3a 3b 3c 3d 3f 3g 3h 3i 3j Nystatin
C. albicans ATCC
2091
1.95 0.12 0.12 0.12 0.24 1.95 1.95 0.98 3.91 0.24
C. albicans ATCC
10231
1.95 0.06 0.12 0.06 0.015 0.48 0.48 0.24 0.48 0.48
C. parapsilosis
ATCC 22019
1.95 0.48 0.48 0.24 0.48 3.91 3.91 0.98 3.91 0.24
C. krusei ATCC
14243
3.91 0.24 0.12 0.06 0.48 7.81 0.98 0.48 0.98 0.24
C. krusei 0.98 0.24 0.12 0.24 0.015 0.03 0.48 0.98 0.06 0.24
C. tropicalis 0.98 0.06 0.12 0.06 0.06 0.06 0.03 0.24 0.015 0.015
C. inconspicua 1.95 0.24 0.98 0.12 0.03 0.48 0.24 0.48 0.98 0.12
C. famata 7.81 0.12 0.12 0.48 0.48 7.81 1.95 1.95 1.95 0.06
C. guilliermondii 1.95 0.12 0.24 0.48 0.48 7.81 0.48 0.98 0.24 0.06
C. lusitaniae 0.98 0.98 0.12 0.12 0.12 0.48 0.24 0.48 0.48 0.12
C. sake 3.91 0.06 0.12 0.12 0.06 0.48 0.98 0.48 0.24 0.06
C. dubliniensis 1.95 0.06 0.03 0.06 0.015 0.24 0.48 0.015 0.24 0.12
C. parapsilosis 3.91 0.12 0.03 0.06 0.12 0.98 1.95 0.24 0.48 0.12
C. albicans 0.98 0.12 0.06 0.12 0.24 0.48 0.98 0.48 0.24 0.24
C. kefyr – 15.62 31.25 1.95 1.95 31.25 7.81 7.81 125 0.12
C. pulcherrima – – 125 15.62 31.25 250 62.5 62.5 7.81 0.12
C. glabrata – 62.5 500 15.62 31.25 15.62 125 31.25 125 0.48
C. lambica – – 125 15.62 31.25 125 125 – 250 0.48
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Four compounds: 3c, 3e, 3f, and 3i (100 mg/kg) which
showed protection in PTZ, MES, or 6-Hz tests were
additionally tested in the rotarod test to assess their impact
on animals’ motor coordination. None of these compounds
impaired motor skills of experimental animals (Fig. 2b-d)
and all animals were able to perform the test at 6 rpm (F
[4,35]= 0.6383, p > 0.05), 18 rpm (F[4,35]= 1.000, p >
0.05) and 24 rpm (F[4,35]= 1.348, p > 0.05).
The main goal of the in vivo part of this study was to
assess anticonvulsant properties of (2-(cyclopropylmethyli-
dene)-hydrazinyl)thiazole 3a–3j in mouse models of sei-
zures. For this purpose we used four distinct screening
assays, i.e., MES, 6-Hz and PTZ and pilocarpine tests.
These tests are regarded “gold standards” in the search for
novel antiepileptic drugs and they allow to predict the
efficacy of anticonvulsant active agents against different
types of seizures in humans (Loescher 2011). The MES test
is useful for selection of drugs for generalized tonic-clonic
seizures, 6-Hz psychomotor seizure model resembles psy-
chomotor seizures occurring in human limbic epilepsy
(Loescher 2011; Loescher and Schmidt 2011) and the PTZ
model of clonic seizures generally refers to non-convulsive
(absence or myoclonic) seizures in humans (Loescher
2011). Pilocarpine model enables to select compounds able
Table 2 The activity data expressed as MFC (µg/ml) and (MFC/MIC) against the reference and clinical strains of fungi
Species MFC (µg/ml) and (MFC/MIC) of the tested compounds
3a 3b 3c 3d 3f 3g 3h 3i 3j Nystatin
C. albicans ATCC
2091
3.91 (2) 0.98 (8) 0.48 (4) 1.95 (16) 1.95 (8) 1.95 (1) 3.91 (2) 3.91 (4) 7.81 (2) 0.24 (1)
C. albicans ATCC
10231
15.62 (8) 0.24 (4) 0.24 (2) 0.24 (4) 0.03 (2) 0.98 (2) 1.95 (4) 1.95 (8) 1.95 (4) 0.48 (1)
C. parapsilosis ATCC
22019
3.91 (2) 1.95 (4) 1.95 (4) 0.98 (4) 3.91 (8) 3.91 (1) 3.91 (1) 7.81 (8) 31.25 (8) 0.48 (2)
C. krusei ATCC 14243 15.62 (4) 0.98 (4) 0.98 (8] 0.48 (8) 0.98 (2) 31.25 (4) 1.95 (2) 1.95 (4) 3.91 (4) 0.24 (1)
C. krusei 1.95 (2) 0.48 (2) 0.48 (4) 0.98 (4) 0.015 (1) 0.48 (16) 7.81 (16) 7.81 (8) 0.12 (2) 0.98 (4)
C. tropicalis 1.95 (2) 0.12 (2) 0.12 (1) 0.12 (2) 0.98 (16) 0.98 (16) 0.98 (32) 1.95 (8) 0.015 (1) 0.06 (4)
C. inconspicua 3.91 (2) 3.91 (16) 3.91 (4) 0.98 (8) 0.98 (32) 1.98 (4) 0.48 (2) 0.98 (2) 1.95 (2) 0.48 (4)
C. famata 62.5 (8) 0.98 (8) 0.98 (8) 3.91 (8) 7.81 (16) 62.5 (8) 3.91 (2) 7.81 (4) 31.25 (16) 0.12 (2)
C. guilliermondii 31.25
(16)
0.48 (4) 0.98 (4) 3.91 (8) 7.81 (16) 31.25 (4) 3.91 (8) 15.62 (16) 0.98 (4) 0.12 (2)
C. lusitaniae 3.91 (4) 1.95 (2) 0.12 (1) 0.48 (4) 0.48 (4) 1.95 (4) 0.98 (4) 1.95 (4) 0.98 (2) 0.24 (2)
C. sake 15.62 (4) 0.24 (4) 0.98 (8) 0.48 (4) 7.81 (128) 3.91 (8) 125 (128) 7.81 (16) 0.98 (4) 0.12 (2)
C. dubliniensis 3.91 (2) 0.06 (1) 0.06 (2) 0.12 (2) 0.06 (4) 0.48 (2) 0.98 (2) 0.12 (2) 0.48 (2) 0.12 (1)
C. parapsilosis 7.81 (2) 0.12 (1) 0.12 (4) 0.24 (4) 0.98 (8) 1.95 (2) 31.25 (16) 0.98 (4) 1.95 (4) 0.48 (4)
C. albicans 3.91 (4) 1.95 (16) 0.98 (16) 0.24 (2) 0.98 (4) 1.95 (4) 15.62 (16) 15.62 (32) 0.48 (2) 0.24 (1)
C. kefyr – >1000
(nd)
>1000
(nd)
7.81 (4) 7.81 (4) 31.25 (1) 125 (16) >1000
(nd)
>1000
(nd)
0.24 (2)
C. pulcherrima – – >1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
0.24 (2)
C. glabrata – >1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
0.48 (1)
C. lambica – – >1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
>1000
(nd)
– >1000
(nd)
0.98 (2)
Table 3 Anticonvulsant activity of compounds 3a–3j in MES test
Compound Dose (mg/kg) X/Ya
Vehicle – 0/6
3a 100 3/8
3b 100 3/8
3c 30 0/8
100 6/8
3d 100 3/8
3e 30 0/8
100 5/8
3f 100 4/8
3g 100 3/8
3h 100 4/8
3i 100 3/8
3j 100 4/8
aResults are shown as number of mice protected (X) per number of
mice tested (Y)
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to cease status epilepticus and drug-resistant epilepsy
(Blanco et al. 2009).
The results obtained in the present study demonstrated a
distinct anticonvulsant activity of the test compounds. In
MES test two compounds—3c and 3e revealed a higher
anticonvulsant activity than other agents tested. Note-
worthy, they were not effective in the PTZ model. This
might indicate for a potential usefulness of 3c and 3e in
tonic-clonic seizures (grand mal epilepsy) in humans but
not in absence seizures. This finding also suggests that their
mechanism of action is likely to be related to the blockade
of voltage-gated sodium channels but not to the inhibition
of T-type calcium channels (Loescher 2011; Loescher and
Schmidt 2011; Brodie et al. 2011).
In contrast to this, the compounds 3f and 3i significantly
delayed the onset of PTZ-induced seizures and they reduced
the number of seizure episodes in PTZ-treated mice. It has
been suggested that compounds showing activity in PTZ
test might be useful in human absence seizures but not in
grand mal epilepsy and their mechanism of action might be
similar to that of ethosuximide—an antagonist of T-type
voltage-gated calcium channels (Loescher 2011; Loescher
and Schmidt 2011). The compound 3i was also effective in
the mouse model of psychomotor seizures, i.e., the 6-Hz
test. To some degree, this anticonvulsant activity of 3i
resembles that of levetiracetam. It should be however
emphasized that 3i was effective in both PTZ and 6-Hz test,
while levetiracetam is active in only in 6-Hz test but not in
PTZ test (Loescher 2011; Loescher and Schmidt 2011).
Pilocarpine evokes spontaneous recurrent seizures that
mimic status epilepticus in humans and is regarded as a
very useful tool to study drug-resistant epilepsy (Blanco
et al. 2009). The four compounds tested did not show
protective properties against pilocarpine-induced seizures.
Motor coordination deficits are one of the most frequent
adverse effects of available antiepileptic drugs and this
effect might be a serious limitation of antiepileptic phar-
macotherapy. Using the rotarod test we demonstrated that
the test compounds at the anticonvulsant active dose do not
induce any motor deficits in experimental animals.
To conclude, in the in vivo part of the present study we
selected four compounds that showed anticonvulsant
activity in screening tests in mice without impairing their
motor skills. The compounds 3f and 3i demonstrated the
highest anticonvulsant activity in PTZ-induced seizures and
3i was also effective in 6-Hz test. In MES test the com-
pounds 3c and 3e were active. Taken together, these com-
pounds can be regarded as interesting novel lead structure in
the search for novel anticonvulsant agents.
anti-Toxoplasma gondii activity
Due to the fact that available literature strongly suggests
that a relationship between toxoplasmosis infection and
epilepsy exists (Ngoungou et al. 2015; Palmer 2007), the
prepared thiazoles 3a–3j have been used to study intensity
of Toxoplasma gondii virulent RH strain intracellular pro-
liferation (%) in the VERO host cells. For this purpose,
Toxoplasma gondii (tachyzoites) of RH strain were incu-
bated with different concentrations of the thiazoles 3a–3j
Fig. 1 Influence of the test compounds 3a–3j on latency time to first
clonus a and the number of seizure episodes b in PTZ-induced seizure
model. Statistical analysis: one way analysis of variance (ANOVA),
followed by Dunnett’s post-hoc test. Significance vs. vehicle-treated
mice: *p < 0.05, **p < 0.01, ***p < 0.001
Table 4 Anticonvulsant activity of compounds 3a–3j measured in 6-
Hz test
Compound Dose (mg/kg) X/Ya
Vehicle – 1/4
3a 100 1/4
3b 100 0/4
3c 100 1/4
3d 100 2/4
3e 100 1/4
3f 100 2/4
3g 100 1/4
3h 100 2/4
3i 30 1/4
100 3/4
3j 100 0/4
aResults are shown as number of mice protected (X) per number of
mice tested (Y)
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ranging from 0.9 to 31.25 μg/ml. The parasite growth
inhibition was monitored by measuring the specific incor-
poration of [3H]uracil in the parasite’s nucleic acids. The
percentages of the parasite proliferation in VERO host cells
by the compounds 3a–3j and the control drug-sulfadiazine,
as well as IC50 values are summarized in Table 5.
According to these results, compounds 3a, 3h and 3j
showed significant anti-Toxoplasma gondii activity, with
IC50 values 31–52 times lower than those observed for
sulfadiazine (IC50= 935.8 μg/ml, see Supporting Informa-
tion for more details). The highest activity showed com-
pounds containing fluorine, cyano and nitro groups.
Cytotoxicity against mouse L929 fibroblast and African
green monkey kidney VERO cells
The next stage of our research was to determine the toxicity
of the newly synthesized compounds. This is a very
important test because it determines whether the investi-
gated compounds will be suitable for further clinical
investigation. To demonstrate that these compounds are safe
for host cells, we decided to investigate the cytotoxic effects
of (2-(cyclopropylmethylidene)hydrazinyl)thiazole (3a–3j)
on mouse L929 fibroblast, as well as the VERO cells using
an MTT assay. The results of the cytotoxicity evaluation,
anti-Candida spp. and anti-Toxoplasma gondii activity
studies showed that Candida spp. and Toxoplasma gondii
growth was inhibited at non-cytotoxic concentrations for the
host cells (Table 6).
Molecular modelling studies
In order to identify potential molecular targets responsible
for antifungal and anticonvulsant activity, the molecular
docking was performed. We have earlier demonstrated that
N-myristoyltransferase (NMT) and secreted aspartic pro-
teinase (SAP) are potential molecular targets for hydrazi-
nylthiazoles. NMT catalyses the reaction of myristate with
important fungal cell proteins (Łączkowski et al. 2014b,
2016e). In contrast, SAP is responsible for the adherence of
fungal cells to host epithelial cells followed by colonization
of the host tissue. Continuing our research on potential
inhibitors of these enzymes, we decided to use them in our
in silico experiments. According to the docking scores
Fig. 2 Influence of the compounds 3c, 3e, 3f, and 3i at the dose of
100 mg/kg on: a latency time to pilocarpine-induced status epilepticus,
or b–d motor coordination measured in the rotarod test. Results are
shown as latency time to status epilepticus (±SEM), or mean time
spent on the rotarod (±SEM) rotating at 6, 18, or 24 rpm. Statistical
analysis: one-way analysis of variance (ANOVA), followed by Dun-
nett’s post-hoc comparison: p > 0.05
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presented in (Table 7), in contrast to docking results in
NMT-binding site, all compounds 3a–3d and 3f–3i are
identified to be binding to the SAP-binding pocket with
affinity only slightly lower than those predicted for native
inhibitor A70450. The overall binding mode of all of them
in their extended conformations is very similar to that of
A70450, with the exception of 3h and 3i for which a slight
shift of their cyclopropane ring outside of the SAP pocket is
predicted (Fig. 3).
The binding positions of 3a–3d and 3f–3i are stabilized
by rich network of intermolecular interactions with sur-
rounding residues and structural water molecules, and most
of these interactions are identical to those observed for
crystal structure of A70450 in complex with SAP. The
binding of the compounds 3f and 3i was also studied by
docking in the transient receptor potential vanilloid 6
(TRPV6) which represent highly calcium-selective ion
channel (Saotome et al. 2016). Studies have shown a wide
distribution of TRPV6 in the brain, which indicates its
broad role in the nervous system functions (Kumar et al.
2017). Both compounds are predicted to bind with higher
affinity (docking scores −19.8 kcal/mol) than native inhi-
bitor (−18.3 kcal/mol) and fenytoine (−16.4 kcal/mol).
Their thiazole ring is positioned close to carboxylic group
of native 6-(5-methyl-2-oxo-imidazolidin-4-yl)hexanoic
acid while the cyclopropane-hydrazine arms are pulled out
of the binding pocket. The calculated binding mode of 3f
and 3i shows two hydrogen bonds between their nitrogen
atoms of hydrazine group and surrounding residues while
for 3i additional H-bond interaction of its terminal azide
group with Gln118 is predicted (data given in Supporting
Information).
Conclusion
We have developed an efficient method for the synthesis of
new thiazole derivatives containing a cyclopropane frag-
ment. Our results indicated that newly synthesized com-
pounds showed very high antifungal activity towards most
reference and clinical strains of Candida spp. Their anti-
microbial effect was similar and even stronger to nystatin
which is a popular antimycotic drug. Additionally, com-
pounds containing chloro and trifluoromethyl substituents
showed an interesting anticonvulsant activities in the MES
test, whereas compounds containing methoxy and azido
substituents demonstrated the anticonvulsant activity in
PTZ-induced seizures. Noteworthy, none of these com-
pounds impaired animals’ motor skills in the rotarod test.
Moreover, compounds 3a, 3h, and 3j showed significant
anti-Toxoplasma gondii activity, with IC50 values 31–52
times lower than those observed for sulfadiazine. The
results of the cytotoxicity evaluation, anti-Candida spp. andTa
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anti-Toxoplasma gondii activity studies showed that Can-
dida spp. and Toxoplasma gondii growth was inhibited at
non-cytotoxic concentrations for the host cells. These data
showed that new compounds may be used for preclinical
investigation in the treatment of candidiasis and microbial
infection-related seizures.
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Table 6 The highest possible
non-cytotoxic concentration of
the compounds [µg/ml] tested on
L929 and VERO cell lines
Thiazole 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j
Conc.a 31.25 7.81 7.81 31.25 3.91 31.25 15.63 31.25 15.63 31.25
aHigher concentrations of the tested compounds could not be reached due to their limited solubility
Table 7 Scores of top poses of
3a–3d and 3f–3i docked to
proteins: SAP and NMT
Molecular targets Docking scores (kcal/mol) Native ligand
3a 3b 3c 3d 3f 3g 3h 3i 3j
SAP −18.0 −15.9 −15.6 −15.9 −13.6 −16.5 −17.8 −20.3 −15.7 −20.4
NMT −19.8 −18.7 −16.9 −17.5 −18.3 −19.1 −17.4 −24.1 −17.3 −36.3
Fig. 3 Overlay of calculated binding modes of (in gray): 3a a and 3h b and native ligand A70450 (in green) in the SAP-binding pocket. Remaining
compounds are predicted to bind in similar manner
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